You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Medications Research Articles
Popular Medications Research Articles
Highly Recommended Medications Research Articles
Send a link to this page to your friends and colleagues.
A Canadian clinical study has delivered a double dose of good news for proponents of exenatide (sold commercially as Byetta), a drug used by more than 700,000 Americans to control blood glucose, ease food cravings, and, incidentally, lose weight.
An experimental long-term version, injected once weekly (versus the twice-daily routine in current use), provides better control of blood sugar and is better tolerated by users' gastrointestinal systems.
Those are the conclusions of a study by Dr. Daniel Drucker and colleagues at the Mount Sinai Hospital and University of Toronto in Ontario, Canada. Dr. Drucker's study was presented at a recent meeting of the European Association for the Study of Diabetes in Rome, and will be published in the British medical journal The Lancet.
The randomized trial followed 259 type 2 diabetes patients who had had diabetes an average of nearly seven years, tracking their A1c levels for 30 weeks. The mean A1c level for the group was 8.3% at the start of the study.
One group of 129 patients received a once-weekly 2 mg (milligram) injection of exenatide. The other group of 130 patients received exenatide injections of 10µg (micrograms) twice daily.
The patients on the once-weekly regimen saw their A1c levels fall to a mean of 6.4% (a -1.9% improvement), while those taking the drug twice daily saw their A1c's fall to 6.8% (a -1.5% improvement).
More patients in the once-weekly group, 77 percent, achieved the study target of an A1c of 7.0% or less, compared with 61 percent of those in the twice-daily group.
The percentages of those achieving A1c's of 6.5% or less were similar in both groups. The authors concluded, "Exenatide once weekly resulted in significantly greater improvements in glycemic control than exenatide given twice a day, with no increased risk of hypoglycemia and similar reductions in bodyweight."
The study is available online.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.